Skip to content

The clinical value of computer three-dimensional reconstruction noninvasive portal pressure detection software to guide accurate treatment of portal hypertension with different degrees of cirrhosis

The clinical value of computer three-dimensional reconstruction noninvasive portal pressure detection software to guide accurate treatment of portal hypertension with different degrees of cirrhosis

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000030132
Enrollment
Unknown
Registered
2020-02-24
Start date
2020-04-01
Completion date
Unknown
Last updated
2020-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhosis portal hypertension

Interventions

control group:conventional treatment based on clinical experience
experimental group:real-time non-invasive pressure detection software portal pressure detection guides treatment

Sponsors

Shanghai Tongji Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Ages 18 to 70 years, regardless of gender; 2. Male or non-pregnant, non-lactating women; 3. The diagnosis of liver cirrhosis is confirmed by imaging, and the etiology of liver cirrhosis is not limited (viral hepatitis, autoimmune liver disease, fatty liver, alcoholic liver disease, genetic metabolic liver disease, etc.); 4. Unlimited stages of cirrhosis: compensatory period, decompensated period, late decompensated period; 5. Good cognitive ability and good compliance; 6. Agree to participate in this project and volunteer to sign the informed consent form;

Exclusion criteria

Exclusion criteria: 1. Patients with severe complications (hemorrhage of the digestive tract, liver coma, bacterial infection, hepatorenal syndrome, etc.) who are expected to survive less than six months; 2. Suspected or confirmed to have malignant tumor disease; 3. Language impaired; 4. People with a history of drug abuse and uncontrolled alcohol abuse; 5. Participated in other clinical trials within 3 months.

Design outcomes

Primary

MeasureTime frame
Complication rate;mortality rate;

Countries

China

Contacts

Public ContactChangqing Yang

Shanghai Tongji Hospital

cqyang@tongji.edu.cn+86 21-66111292

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026